TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study of Il-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria :~* Age \[7-13\] years for girls and \[7-14\] years for boys~  * With a T1D diagnosis (as ADA)~ * Treated with insulin for ≤ 3 months,~ * With at least one auto-antibody among: anti-insulin, anti-GAD, anti-IA2, anti-ZnT8 ;~* No clinically relevant abnormal findings for haematology, biochemistry, liver and kidney functions~* Informed consent signed by the patient, the parents, and the investigator before any intervention necessary for the trial.~Exclusion criteria :~* Contra-indications to IL-2 :~  * Hyper sensibility to IL-2 or its excipients,~ * Severe cardiopathy~ * Previous organ allograft~ * Ongoing infection requiring antibiotherapy,~ * O2 Saturation ≤ 90 %~ * Severe impairment of any vital organ~ * Documented history of other auto-immune diseases (except for auto-antibodies for, IAA, GADA, IA-2A, anti-ZnT8A, and stable thyroiditis with normal TSH (\<10 mUI/L), T3 and, T4 levels.~ * Diabetes onset characteristics including:~    * Continuous nocturnal polyuria ≥ 3 months ;~   * Inaugural acidosis (with venous Ph \< 7.25) ;~   * HbA1c at diagnostic ≥ 13%;~   * Weight loss ≥ 10 % at diagnosis ;~   * Positive autoantibodies to 21-hydroxylase~   * Stage 2 obesity~* Non authorized concomitant treatment : immuno-modulators, cytotoxic drugs, drug modifying plasma glycemia~* vaccination ≤ 4 weeks with life vaccin~* Positive serology (IgM) to the Epstein-Barr virus (EBV) and/or cytomegalovirus (CMV), reflecting an acute infection.~* Participation to another clinical investigation in previous 3 months~* No affiliation to National Health Insurance

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- interleukin-2 (Type: EXPERIMENTAL): Dose D1 of interleukin-2
- Dose D2 of interleukin-2 (Type: EXPERIMENTAL): Dose D2 of interleukin-2
- Dose D3 of interleukin-2 (Type: EXPERIMENTAL): Dose D3 of interleukin-2
- placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who suffer from tooth sensitivity~Inclusion Criteria:~- none

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Dentifrice containing stannous fluoride
- Arm 2 (Type: ACTIVE_COMPARATOR): Marketed dentifrice containing Sodium Monofluorophosphate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Probiotics on Oral Health

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Adolescent - ASA I \& II~* No Antibiotics use~* No intake of commercially available probiotics products during the intervention~Exclusion Criteria:~* Adolescents have ASA III or IV~* Antibiotics use~* refuse to stop taking commercially available probiotics products during intervention

- Gender: MALE
- Minimum Age: 13 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- Probiotics (Type: EXPERIMENTAL): participants will receive a lozenge containing mixture of probiotic bacteria BB-12 and LGG
- Control - No probiotics (Type: PLACEBO_COMPARATOR): Participants will receive a control lozenge containing no probiotics. all lozenges are sugar-free; sweetened by xylitol (0.5 g xylitol per piece)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Breast cancer with evidence of unresectable, locally recurrent, or metastatic disease.~* Tumors over-expressing Her-2~* Candidate for treatment with docetaxel/trastuzumab~Exclusion Criteria:~* Histology of inflammatory carcinoma~* AST and/or ALT \>1.5 x ULN concomitant with ALP \>2.5 x ULN

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Combination of SU011248 (37.5 mg once daily \[Schedule 2/1\]) with docetaxel (75 mg/m2 every 3 weeks) and trastuzumab (therapeutic dose)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Triple-negative breast cancer~* Older than 18 years old~* Have tumor resection surgery~* Sufficient organ function (marrow, heart, liver)~Exclusion Criteria:~* Other malignancy~* Other serious disease( marrow, heart, liver)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- EC-T (Type: ACTIVE_COMPARATOR): None
- TP (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Phase I study: patients with advanced carcinomatosis from ovarian, breast, gastric, or pancreatic origin. No alternative systemic treatment options are available.~* Age over 18 years~* Adequate performance status (Karnofsky index \> 60%)~* Absence of intestinal or urinary obstruction~* Limited size of the majority of peritoneal tumor implants (\< 5 mm)~* Absent or limited ascites~* Ability to understand the proposed treatment protocol and provide informed consent~* Expected life expectancy more than 6 months~* Laboratory data~  * Serum creatinine ≤ 1.5 mg/dl or a calculated GFR (CKD-EPI) ≥ 60 mL/min/1.73 m²~ * Serum total bilirubin ≤ 1.5 mg/dl, except for known Gilbert's disease~ * Platelet count \> 100.000/µl~ * Hemoglobin \> 9g/dl~ * Neutrophil granulocytes \> 1.500/ml~ * No major blood coagulation disorders. Parameters within normal range.~* Absence of alcohol and/or drug abuse~* No other concurrent malignant disease~* Written informed consent~Exclusion Criteria:~* Pregnancy or breast feeding. Women who can become pregnant must ensure effective contraception.~* Active bacterial, viral or fungal infection~* Active gastro-duodenal ulcer~* Parenchymal liver disease (any stage cirrhosis)~* Uncontrolled diabetes mellitus~* Psychiatric pathology affecting comprehension and judgement faculty~* General or local (abdominal) contra-indications for laparoscopic surgery~* Documented intolerance or allergy to paclitaxel~* Patients who receive other taxane therapy until three weeks before the first experimental treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abraxane 35 mg/m² (Type: EXPERIMENTAL): PIPAC with Abraxane (35 mg/m²) will be administered every 4 weeks for 3 cycles.
- Abraxane 70 mg/m² (Type: EXPERIMENTAL): PIPAC with Abraxane (70 mg/m²) will be administered every 4 weeks for 3 cycles.
- Abraxane 90 mg/m² (Type: EXPERIMENTAL): PIPAC with Abraxane (90 mg/m²) will be administered every 4 weeks for 3 cycles.
- Abraxane 112.5 mg/m² (Type: EXPERIMENTAL): PIPAC with Abraxane (112.5 mg/m²) will be administered every 4 weeks for 3 cycles.
- Abraxane 140 mg/m² (Type: EXPERIMENTAL): PIPAC with Abraxane (140 mg/m²) will be administered every 4 weeks for 3 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion¨Criteria:~1. Patients must have relapsed / refractory AML according to WHO classification (excluding acute promyelocytic leukaemia)~2. Patients must have ECOG Performance Status (PS) of 0 - 2~3. Patients must be 18 years of age or older~4. Women of child-bearing potential must have a negative serum or urine pregnancy test within two weeks prior to treatment start~5. Male and female fertile patients must use adequate contraception for the duration of the study, and males also for 3 months after the last elacytarabine dose~6. Patients must be capable of understanding and complying with protocol requirements, and they must be able and willing to sign a written informed consent~Exclusion Criteria:~1. A history of allergic reactions to egg. A history of CTCAE grade 3 or 4 allergic reactions to ara-C of~2. A history of cancer that according to the investigator might confound the assessment of the endpoints of the clinical study~3. Known positive status for human immunodeficiency virus (HIV)~4. Pregnant and nursing patients~5. Uncontrolled inter-current illness including, but not limited to, uncontrolled infection, or psychiatric illness/social situations that will limit compliance with study requirements~6. Impairment of hepatic or renal function to such an extent that the patient, in the opinion of the investigator, will be exposed to an excessive risk if entered into the clinical study~7. Active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, arrhythmias not controlled by medications, or uncontrolled congestive heart failure. Any NYHA grade 3 or 4~8. A history of familial long QT syndrome~9. Patients with history of serious ventricular arrhythmia (VT or VT)~10. ECG criteria at the eligibility visit: QTc ≥ 480 msec calculated using Fridericia's correction (QTcF = QT/RRO,33) or bradycardia (\<50bpm) or criteria for left ventricular hypertrophy~11. treatment with any medications known to produce QT prolongations~12. Treatment with hydroxyurea or 6-mercaptopurine within the last 12 hours prior to treatment on this protocol or any other investigational or standard cytotoxic treatment within the last 14 days~9. Any medical condition which in the opinion of the investigator places the patient at an unacceptably high risk for toxicities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mechanisms of Walking Recovery After Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age 30-90 years~* unilateral stroke experienced \>6 months prior to enrollment in middle cerebral artery (MCA) territory without complete disruption of the putamen on the lesion side~* walking speed \<= 1.0 m/s on the 10 meter walk test~* able to walk 10m over ground with assistive devices as needed and no physical assistance~Exclusion Criteria:~* MRI incompatibility (e.g. metallic or electronic implants, severe claustrophobia)~* inability to perform mental imagery (time dependent motor imagery screening test \[TDMI\])~* evidence of significant arrhythmia or myocardial ischemia on treadmill ECG stress test, or significant baseline ECG abnormalities that would make an exercise ECG uninterpretable~* recent (\<3 months) cardiopulmonary hospitalization~* unable to communicate with investigators or correctly answer consent comprehension questions~* significant ataxia or neglect (score of 2 on NIH stroke scale item 7 or 11)~* severe lower extremity (LE) spasticity (Ashworth \>2)~* recent (\<3 months) illicit drug or alcohol abuse or significant mental illness~* major post-stroke depression (PHQ-9 ≥10) in the absence of medical management~* participating in physical therapy or another interventional research study;~* recent (\<3 months) paretic LE botulinum toxin injection~* concurrent progressive neurologic disorder or other major medical, orthopedic or peripheral vascular conditions that would limit improvement~* pregnancy

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): 4-week control period with no intervention and 4-weeks of high-intensity interval training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be diagnosed with multiple myeloma that is progressing after at least 2 cycles of anti-myeloma treatment or that has relapsed with progressive disease after treatment.~* Subjects must discontinue all anti-myeloma drug or non-drug therapy prior to the first dose of study drug with the exception of radiation therapy initiated prior to baseline.~* Females of childbearing potential must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence.~Exclusion Criteria:~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide plus Dexamethasone (Type: EXPERIMENTAL): Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient is being treated with a serotonin reuptake inhibitor (SRI) antidepressant (monotherapy) that was prescribed to treat Major Depressive Episode (DSM-IV-TR criteria)~* The response to the current SRI treatment is inadequate and patient agrees to discontinue the current SRI at the baseline~* Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥22 at the Screening Visit and Baseline~* The patient, if a woman, must: agree not to try to become pregnant during the study, AND use adequate, highly effective contraception~Exclusion Criteria:~* The patient has any current Axis I disorders (DSM-IV criteria) other than Major Depressive Disorder (MDD), General Anxiety Disorder (GAD) and Social Anxiety Disorder (SAD)~* The patient is at significant risk of suicide~* The patient is currently receiving formal psychotherapy or other psychoactive medications~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine 10 mg or 20 mg (Type: EXPERIMENTAL): None
- Agomelatine 25 mg or 50 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cancer in Patients With Gabapentin (GPRD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The study cohort from which cases and controls are drawn is all subjects in the UK GPRD 1993-2008. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993. Follow-up ends Dec 31, 2008, or earlier if the subject leaves the GPRD for any reason including death.~Exclusion Criteria:~* Subjects are excluded from the GPRD cohort if they have a cancer diagnosis or a history of cancer prior to the cohort entry date. Cases and controls will be required to have at least 2 years of follow-up in the study cohort before their index date (For cases, the index date is the date of first diagnosis of the respective cancer. The index date for controls is set as the date at which the follow-up time from cohort entry is the same as the case.) Cases must have no history of any other cancer diagnosis prior to the index date. Controls are required to be free of cancer diagnosis in the database up to the control's index date.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- UK GPRD 1993-2008 (Type: None): The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993. Subjects are excluded from the GPRD cohort if they have a cancer diagnosis or a history of cancer prior to the cohort entry date.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infection, as documented by a rapid HIV-1 test or any FDA-approved HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit and confirmed by western blot at any time prior to study entry. Alternatively, two HIV-1 RNA values \> 200 copies/mL at least 24 hours apart performed by any laboratory that has CLIA certification, or its equivalent may be used to document infection.~* Patients must be ≥ 18 years of age.~* Plan to undergo a Myeloablative, HLA matched or partially HLA-mismatched (haploidentical), related-donor bone marrow transplantation that includes high-dose posttransplantation Cy using bone marrow from a related donor:~* Plan to undergo a Nonmyeloablative, HLA matched or partially HLA-mismatched, related-donor bone marrow transplantation that includes high-dose posttransplantation Cy using bone marrow from a related donor:~Exclusion Criteria:~* Patients with a known history of enfuvirtide resistance will not be eligible for this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enfuvirtide monotherapy (Type: EXPERIMENTAL): Enfuvirtide 90 mg subcutaneously every 12 hours will be also be administered during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions with conditioning regimens in patients who require ritonavir-boosted PI containing ART regimens.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete